Trisadhd

Trisadhd.com serves as the patient and caregiver-facing portal for Tris Pharma's portfolio of Attention Deficit Hyperactivity Disorder (ADHD) treatments. Tris Pharma is a fully integrated pharmaceutical company that operates in the central nervous system (CNS) therapeutic area, with a specialized focus on developing and commercializing medications for ADHD. The company's business model revolves around the research, development, manufacturing, and commercialization of branded pharmaceutical products. Revenue is generated through the sale of these prescription medications to pharmacies and distributors, which are then prescribed by healthcare professionals to patients.

The history of the assets now under Tris Pharma's ADHD division involves several key corporate milestones. NextWave Pharmaceuticals, founded in 2005 by Mahendra Shah in partnership with venture capital firms, initially focused on developing products for CNS and cardiovascular diseases. NextWave, in collaboration with Tris Pharma, co-developed two key ADHD treatments, Quillivant XR and QuilliChew ER, utilizing Tris's proprietary LiquiXR® drug delivery technology. This platform allows for the creation of extended-release liquid, chewable, and tablet medications, providing flexible dosing and administration options, which is particularly beneficial for pediatric patients. In 2012, Pfizer acquired NextWave Pharmaceuticals, but Tris Pharma continued to manufacture the products. Subsequently, in a strategic move to bring the commercialization of these products in-house and solidify its position in the ADHD market, Tris Pharma acquired NextWave from Pfizer in September 2018. This acquisition integrated Quillivant XR and QuilliChew ER into Tris's existing ADHD portfolio, which already included DYANAVEL XR, an amphetamine-based treatment launched in 2016.

The company's product line addresses the needs of patients aged six and older, offering both methylphenidate-based (Quillivant XR, QuilliChew ER) and amphetamine-based (DYANAVEL XR) stimulant options. Quillivant XR is the first extended-release oral liquid methylphenidate, and QuilliChew ER is the first extended-release methylphenidate chewable tablet. These formulations provide a significant benefit by offering once-daily dosing with symptom control that can last up to 12 hours, a feature designed to help patients manage symptoms throughout the school or work day. The products are central nervous system stimulants, which are federally controlled substances due to their potential for abuse and dependence. Tris Pharma markets these treatments directly to healthcare professionals and provides resources such as savings cards for eligible patients to reduce out-of-pocket costs.

Keywords: Tris Pharma, NextWave Pharmaceuticals, ADHD treatment, central nervous system, CNS stimulants, Quillivant XR, QuilliChew ER, DYANAVEL XR, methylphenidate, amphetamine, LiquiXR technology, extended-release, pediatric medication, pharmaceutical manufacturing, Pfizer acquisition, specialty pharmaceuticals, ADHD medication, healthcare professional portal, patient support